Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment

Clinical trial NCT04511455 · COMPLETED

Trial details

NCT number: NCT04511455
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma Non-resectable Metastatic Hepatocellular Carcinoma

Start date: 2020-12-08
Primary completion: 2024-12-31
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.